Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of 177Lu-DOTATATE PRRT

Eva Medaer, Chris Verslype, Eric Van Cutsem, Jeroen Dekervel, Paul M. Clement, Kristiaan Nackaerts, Annouschka Laenen, Olivier Gheysens, Karolien Goffin, Sander Jentjens, Koen Van Laere & Christophe M. Deroose
Background: Peptide receptor radionuclide therapy (PRRT) is a validated treatment for somatostatin receptor overexpressing neuroendocrine tumors (NETs). The NETTER-1 trial demonstrated a pronounced positive effect on progression-free-survival compared to high dose somatostatin analogs (SSAs), with a strong tendency toward overall survival benefit. Our aim was to investigate the influence of pretreatment with everolimus and/or sunitinib on subacute hematotoxicity of PRRT. To assess the influence of prior treatment with everolimus/sunitinib might be of clinical relevance due...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.